Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model

Open access

Abstract

Brain derived neurotrophic factor (BDNF) promotes the growth, differentiation, maintenance and survival of neurons. These attributes make BDNF a potentially powerful therapeutic agent. However, its charge, instability in blood, and poor blood brain barrier (BBB) penetrability have impeded its development. Here, we show that engineered clathrin triskelia (CT) conjugated to BDNF (BDNF-CT) and delivered intranasally increased hippocampal BDNF concentrations 400-fold above that achieved previously with intranasal BDNF alone. We also show that BDNF-CT targeted Tropomyosin receptor kinase B (TrkB) and increased TrkB expression and downstream signaling in iTat mouse brains. Mice were induced to conditionally express neurotoxic HIV Transactivator-of-Transcription (Tat) protein that decreases BDNF. Down-regulation of BDNF is correlated with increased severity of HIV/neuroAIDS. BDNF-CT enhanced neurorestorative effects in the hippocampus including newborn cell proliferation and survival, granule cell neurogenesis, synaptogenesis and increased dendritic integrity. BDNF-CT exerted cognitive-enhancing effects by reducing Tat-induced learning and memory deficits. These results show that CT bionanoparticles efficiently deliver BDNF to the brain, making them potentially powerful tools in regenerative medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-022-03177-3

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BDNF-Clathrin (BDNF-CT) nanoparticle purification and characterization. Transmission electron microscopy (TEM) images show (a) clathrin coated vesicles (CCVs) isolated from pig brains, and (b) purified clathrin triskelia (CT) with attached metal (Gd) negatively stained with 1% uranyl acetate. (c) A graphical representation of a clathrin triskelion with three heavy chains (CHCs, yellow, blue and green) and three light chains (CLCs, red). One BDNF molecule is conjugated to the each CHC via PEG and NP solution had 2.25 mg/ml of protein (2 mg/ml of CT with 0.25 mg/ml of BDNF). (d) SDS-PAGE shows CCV, CT, and BDNF-CT protein bands. The CHC molecular weight increased by 30 kDa following BDNF conjugation to CT. (e) Dynamic light scattering (DLS) studies show the mean hydrodynamic radius (RH) of unconjugated CT to be 16.8 ± 5.6 nm. (f) The mean RH increased to 35.1 ± 12.6 nm after BDNF PEGylation and subsequent conjugation to CT.
Fig. 1 BDNF-Clathrin (BDNF-CT) nanoparticle purification and characterization. Transmission electron microscopy (TEM) images show (a) clathrin coated vesicles (CCVs) isolated from pig brains, and (b) purified clathrin triskelia (CT) with attached metal (Gd) negatively stained with 1% uranyl acetate. (c) A graphical representation of a clathrin triskelion with three heavy chains (CHCs, yellow, blue and green) and three light chains (CLCs, red). One BDNF molecule is conjugated to the each CHC via PEG and NP solution had 2.25 mg/ml of protein (2 mg/ml of CT with 0.25 mg/ml of BDNF). (d) SDS-PAGE shows CCV, CT, and BDNF-CT protein bands. The CHC molecular weight increased by 30 kDa following BDNF conjugation to CT. (e) Dynamic light scattering (DLS) studies show the mean hydrodynamic radius (RH) of unconjugated CT to be 16.8 ± 5.6 nm. (f) The mean RH increased to 35.1 ± 12.6 nm after BDNF PEGylation and subsequent conjugation to CT.CC BY · PubMed Central
Fig. 2 CT efficiently delivered BDNF to TrkB receptors in the mouse brain. Tat+ mice were given a single dose of i.n. BDNF-CT-Rho (0.3 mg/kg of BDNF and 2.4 mg/kg of CT). Brains were collected after 4 h. Brain sections were probed for TrkB and visualized using Alexa Fluor 488. Confocal microscopy shows TrkB receptors (green) (a, b) and intranasally delivered BDNF-CT-Rho (red) nanoparticles (c, d). BDNF-CT-Rho are co-localized with TrkB receptors (yellow) (e, f). Images were taken from two DG locations (box; g, h). Scale bars are 2 µm. Representative images of the BDNF-CT-Rho are shown in the frontal cortex (FC) (i), striatum (STR) (j), hippocampus (HPC) (k), and hypothalamus (HTH) (l). Brains were also collected from Tat+ mice at 2, 4, and 24 h after i.n. [3]H-BDNF-CT NP administration. Tissue concentrations of radioactive [3]H-BDNF-CT were assessed. The peak concentrations of BDNF-CT in the FC (m), ST (n), HPC (o), and HTH (p) were achieved 4 h after administration. Data are represented as the mean % of the injected dose per gram (% ID/g) of tissue (n = 3/group and for 24 h n = 2/group). Error bars represent S.E.M. The scale bar is 50 µm.
Fig. 2 CT efficiently delivered BDNF to TrkB receptors in the mouse brain. Tat+ mice were given a single dose of i.n. BDNF-CT-Rho (0.3 mg/kg of BDNF and 2.4 mg/kg of CT). Brains were collected after 4 h. Brain sections were probed for TrkB and visualized using Alexa Fluor 488. Confocal microscopy shows TrkB receptors (green) (a, b) and intranasally delivered BDNF-CT-Rho (red) nanoparticles (c, d). BDNF-CT-Rho are co-localized with TrkB receptors (yellow) (e, f). Images were taken from two DG locations (box; g, h). Scale bars are 2 µm. Representative images of the BDNF-CT-Rho are shown in the frontal cortex (FC) (i), striatum (STR) (j), hippocampus (HPC) (k), and hypothalamus (HTH) (l). Brains were also collected from Tat+ mice at 2, 4, and 24 h after i.n. [3]H-BDNF-CT NP administration. Tissue concentrations of radioactive [3]H-BDNF-CT were assessed. The peak concentrations of BDNF-CT in the FC (m), ST (n), HPC (o), and HTH (p) were achieved 4 h after administration. Data are represented as the mean % of the injected dose per gram (% ID/g) of tissue (n = 3/group and for 24 h n = 2/group). Error bars represent S.E.M. The scale bar is 50 µm.CC BY · PubMed Central
Fig. 3 CT are required for BDNF delivery to the hippocampus and increased Akt expression and signaling. Tat+ mice received i.p. Dox and one of four i.n. treatments (BDNF, Sal, CT, or BDNF-CT) daily for 4 days (a). Global control (Tat−) mice received i.p. and i.n. saline (Tat-/Sal). The hippocampal tissue shows increased mBDNF (b), proBDNF (c), mBDNF/proBDNF ratio (d), Akt (e), pAkt (f), and the pAkt/Akt ratio (g) in Tat+ mice that received BDNF-CT vs. other treatments (*P < 0.05, **P < 0.01 and ***P < 0.001), as well as vs. saline treated Tat- mice (#P < 0.05 and ##P < 0.01, ###P < 0.001). Tat+ mice treated with BDNF-CT or Sal had higher pAkt/Akt ratios (g) compared to Tat- controls but levels of Akt and pAkt were significantly higher in BDNF-CT vs. Sal treated Tat+ mice indicating enhanced Akt expression and signaling only with BDNF-CT NPs. Representative WB images are shown (h, i). Data are shown as the mean % change from Tat- control (Tat-/Sal) represented by dotted lines (n = 4–5 per group, five cohorts were processed in parallel). Error bars represent S.E.M.
Fig. 3 CT are required for BDNF delivery to the hippocampus and increased Akt expression and signaling. Tat+ mice received i.p. Dox and one of four i.n. treatments (BDNF, Sal, CT, or BDNF-CT) daily for 4 days (a). Global control (Tat−) mice received i.p. and i.n. saline (Tat-/Sal). The hippocampal tissue shows increased mBDNF (b), proBDNF (c), mBDNF/proBDNF ratio (d), Akt (e), pAkt (f), and the pAkt/Akt ratio (g) in Tat+ mice that received BDNF-CT vs. other treatments (*P < 0.05, **P < 0.01 and ***P < 0.001), as well as vs. saline treated Tat- mice (#P < 0.05 and ##P < 0.01, ###P < 0.001). Tat+ mice treated with BDNF-CT or Sal had higher pAkt/Akt ratios (g) compared to Tat- controls but levels of Akt and pAkt were significantly higher in BDNF-CT vs. Sal treated Tat+ mice indicating enhanced Akt expression and signaling only with BDNF-CT NPs. Representative WB images are shown (h, i). Data are shown as the mean % change from Tat- control (Tat-/Sal) represented by dotted lines (n = 4–5 per group, five cohorts were processed in parallel). Error bars represent S.E.M.CC BY · PubMed Central
Fig. 4 BDNF-CT increased newborn cell survival, proliferation, and neurogenesis. Tat+ mice received i.p. Dox (100 mg/kg) and i.n. saline or BDNF-CT (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) daily for 7 days. Tat− controls received i.p. and i.n. saline. All mice received BrdU (50 mg/kg, i.p. every 12 h) on days 1 and 2 and were sacrificed on the 7th day. Hippocampal sections containing the granule cell layer (GLC) were evaluated for BrdU+, Ki67+, and DCX+ cells using IHC with nickel enhanced DAB staining (black). Densities of BrdU+ cells (a), Ki67+ cells (b), and DCX+ cells (c) are higher in BDNF-CT-treated Tat+ mice vs. matched controls (Tat+ and Tat−) that received saline. Data are represented as the mean density. Error bars represent S.E.M. (n = 4–6 per group, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Images represent BrdU+ (d–f), Ki67+ (g–i) or DCX+ (j–l) staining (black) in the hippocampal GCL following administration of Sal/Sal to Tat− mice, and Dox/Sal or Dox/BDNF-CT to Tat+ mice. Higher magnification of the marked area (l) with DCX+ cells are shown (m). Color saturation is 0% and scale bars are 50 µm.
Fig. 4 BDNF-CT increased newborn cell survival, proliferation, and neurogenesis. Tat+ mice received i.p. Dox (100 mg/kg) and i.n. saline or BDNF-CT (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) daily for 7 days. Tat− controls received i.p. and i.n. saline. All mice received BrdU (50 mg/kg, i.p. every 12 h) on days 1 and 2 and were sacrificed on the 7th day. Hippocampal sections containing the granule cell layer (GLC) were evaluated for BrdU+, Ki67+, and DCX+ cells using IHC with nickel enhanced DAB staining (black). Densities of BrdU+ cells (a), Ki67+ cells (b), and DCX+ cells (c) are higher in BDNF-CT-treated Tat+ mice vs. matched controls (Tat+ and Tat−) that received saline. Data are represented as the mean density. Error bars represent S.E.M. (n = 4–6 per group, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Images represent BrdU+ (d–f), Ki67+ (g–i) or DCX+ (j–l) staining (black) in the hippocampal GCL following administration of Sal/Sal to Tat− mice, and Dox/Sal or Dox/BDNF-CT to Tat+ mice. Higher magnification of the marked area (l) with DCX+ cells are shown (m). Color saturation is 0% and scale bars are 50 µm.CC BY · PubMed Central
Fig. 5 BDNF-CT rescues neurogenesis from Tat-induced toxicity in the hippocampus. Tat+ mice received i.p. Dox and i.n. saline or BDNF-CT nanoparticles (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) daily for 7 days. Tat− controls received i.p. and i.n. saline. All mice received BrdU (50 mg/kg, i.p. every 12 h) on days 1 and 2 and were sacrificed on the 7th day (a). Hippocampal sections containing the granule cell layer were evaluated and double labeled cells (BrdU+ and DCX+) are expressed as the percentage of BrdU+ cells (b). The mean percentage was higher in BDNF-CT-treated Tat+ mice vs. matched controls (Tat+ and Tat−) that received saline, and was lower in Tat+ vs. Tat− mice. BrdU+ cells (red, c–e), DCX+ cells (green, f–h) and double labeled cells (BrdU+ and DCX+) (i–k) are shown. Nuclei (blue) were labeled with DAPI. Data are represented as the mean percentage. Error bars represent S.E.M. (n = 3 per group; *P < 0.05, **P < 0.01, and ***P < 0.001). Scale bars are 50 µm.
Fig. 5 BDNF-CT rescues neurogenesis from Tat-induced toxicity in the hippocampus. Tat+ mice received i.p. Dox and i.n. saline or BDNF-CT nanoparticles (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) daily for 7 days. Tat− controls received i.p. and i.n. saline. All mice received BrdU (50 mg/kg, i.p. every 12 h) on days 1 and 2 and were sacrificed on the 7th day (a). Hippocampal sections containing the granule cell layer were evaluated and double labeled cells (BrdU+ and DCX+) are expressed as the percentage of BrdU+ cells (b). The mean percentage was higher in BDNF-CT-treated Tat+ mice vs. matched controls (Tat+ and Tat−) that received saline, and was lower in Tat+ vs. Tat− mice. BrdU+ cells (red, c–e), DCX+ cells (green, f–h) and double labeled cells (BrdU+ and DCX+) (i–k) are shown. Nuclei (blue) were labeled with DAPI. Data are represented as the mean percentage. Error bars represent S.E.M. (n = 3 per group; *P < 0.05, **P < 0.01, and ***P < 0.001). Scale bars are 50 µm.CC BY · PubMed Central
Fig. 6 BDNF-CT enhanced synaptogenesis and dendritic integrity in the Tat+ mouse hippocampus. Tat+ mice received i.p. Dox (100 mg/kg) and i.n. saline or BDNF-CT (0.23 mg/kg of BDNF and 1.85 mg/kg of CT) daily for 7 days. Cognitive testing started on the 8th day and lasted for 5 days (a). Mice were sacrificed on day 12 and hippocampal dentate gyrus (DG), CA1 and CA3 sections were evaluated for SYP+ (b) (red) and MAP2+ (c) (green) staining. The SYP (d) and MAP2 (e) immunoreactivities (IR) increased in the hippocampal DG, CA1, and CA3 regions in BDNF-CT-treated Tat+ mice vs. saline treated controls. Data are shown as the mean % change from saline treated controls. Error bars represent S.E.M. (n = 6–8 per group; *P < 0.05, **P < 0.01, ***P = 0.001). Scale bars are 100 µm.
Fig. 6 BDNF-CT enhanced synaptogenesis and dendritic integrity in the Tat+ mouse hippocampus. Tat+ mice received i.p. Dox (100 mg/kg) and i.n. saline or BDNF-CT (0.23 mg/kg of BDNF and 1.85 mg/kg of CT) daily for 7 days. Cognitive testing started on the 8th day and lasted for 5 days (a). Mice were sacrificed on day 12 and hippocampal dentate gyrus (DG), CA1 and CA3 sections were evaluated for SYP+ (b) (red) and MAP2+ (c) (green) staining. The SYP (d) and MAP2 (e) immunoreactivities (IR) increased in the hippocampal DG, CA1, and CA3 regions in BDNF-CT-treated Tat+ mice vs. saline treated controls. Data are shown as the mean % change from saline treated controls. Error bars represent S.E.M. (n = 6–8 per group; *P < 0.05, **P < 0.01, ***P = 0.001). Scale bars are 100 µm.CC BY · PubMed Central
Fig. 7 BDNF-CT ameliorated Tat-induced learning and memory deficits and enhanced cognitive flexibility in the Novel object recognition test (NORT) and Barnes maze test (BMT). Tat+ mice received i.p. Dox (100 mg/kg) and either i.n. saline or BDNF-CT daily for 7 days. Testing procedures started on the 8th day and lasted for 5 days. (a) NORT Phase 3 Recognition Index (RI) was significantly higher in Tat+ mice treated daily with a high dose (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) but not a low dose (0.15 mg/kg of BDNF and 1.2 mg/kg of CT) of NPs compared to saline (n = 5–10 per group). (b) Representative heat maps show time spent in different locations of the NORT testing chamber. In the BMT, the latency to locate and enter the escape hole in the acquisition (c) and reversal learning (d) phases was lower in Tat+ mice treated with BDNF-CT vs. saline. Representative diagrams show paths from the starting position (blue dot) to the escape hole (red dot) on day 3 of acquisition phase (e) and trials 2 and 4 of reversal learning phase (f) (top and bottom, respectively). The number of reference errors (g, h) was significantly lower in BDNF-CT compared to saline treated Tat+ mice only in the reversal learning phase (h) of BMT. Data are represented as the mean. Error bars represent S.E.M. Overall treatment differences in the BMT are indicated by #P < 0.05 and ##P < 0.01. Between-subjects post hoc analysis in the NORT is indicated by *P < 0.05.
Fig. 7 BDNF-CT ameliorated Tat-induced learning and memory deficits and enhanced cognitive flexibility in the Novel object recognition test (NORT) and Barnes maze test (BMT). Tat+ mice received i.p. Dox (100 mg/kg) and either i.n. saline or BDNF-CT daily for 7 days. Testing procedures started on the 8th day and lasted for 5 days. (a) NORT Phase 3 Recognition Index (RI) was significantly higher in Tat+ mice treated daily with a high dose (0.3 mg/kg of BDNF and 2.4 mg/kg of CT) but not a low dose (0.15 mg/kg of BDNF and 1.2 mg/kg of CT) of NPs compared to saline (n = 5–10 per group). (b) Representative heat maps show time spent in different locations of the NORT testing chamber. In the BMT, the latency to locate and enter the escape hole in the acquisition (c) and reversal learning (d) phases was lower in Tat+ mice treated with BDNF-CT vs. saline. Representative diagrams show paths from the starting position (blue dot) to the escape hole (red dot) on day 3 of acquisition phase (e) and trials 2 and 4 of reversal learning phase (f) (top and bottom, respectively). The number of reference errors (g, h) was significantly lower in BDNF-CT compared to saline treated Tat+ mice only in the reversal learning phase (h) of BMT. Data are represented as the mean. Error bars represent S.E.M. Overall treatment differences in the BMT are indicated by #P < 0.05 and ##P < 0.01. Between-subjects post hoc analysis in the NORT is indicated by *P < 0.05.CC BY · PubMed Central
Fig. 8 Improvements in memory and cognitive flexibility during BMT reversal leaning task are associated with enhanced hippocampal synaptogenesis and dendritic integrity. The mean latency percent change from the maximum time allowed to find an escape hole in the BMT reversal learning phase (reversal latency %Change) versus the mean CA1, DG, and CA3 hippocampal SYP (a–c) and MAP2 (d–f) immunoreactivities (IR, normalized to Tat+/Sal controls) are shown. The reference errors least square means versus the mean CA1, DG, and CA3 hippocampal SYP (g–i) and MAP2 (j–l) immunoreactivities (normalized to Tat+/Sal controls) are shown. Correlation Coefficients (r) were determined by calculating Pearson product-moment correlations for CA1, DG, and CA3 hippocampal regions. Significant correlations (P < 0.05) are indicated by *.
Fig. 8 Improvements in memory and cognitive flexibility during BMT reversal leaning task are associated with enhanced hippocampal synaptogenesis and dendritic integrity. The mean latency percent change from the maximum time allowed to find an escape hole in the BMT reversal learning phase (reversal latency %Change) versus the mean CA1, DG, and CA3 hippocampal SYP (a–c) and MAP2 (d–f) immunoreactivities (IR, normalized to Tat+/Sal controls) are shown. The reference errors least square means versus the mean CA1, DG, and CA3 hippocampal SYP (g–i) and MAP2 (j–l) immunoreactivities (normalized to Tat+/Sal controls) are shown. Correlation Coefficients (r) were determined by calculating Pearson product-moment correlations for CA1, DG, and CA3 hippocampal regions. Significant correlations (P < 0.05) are indicated by *.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 133 references

Cited by

See all 48

Metadata

Authors
Vitaliano, G. D., Kim, J. K., Kaufman, M. J., Adam, C. W., Zeballos, G., Shanmugavadivu, A., Subburaju, S., McLaughlin, J. P., Lukas, S. E., & Vitaliano, F.
Affiliations
  • Harvard University (US)
  • McLean Hospital (US)
  • University of Florida (US)
  • Boston Consulting Group (United States) (US)
Corresponding author
Vitaliano, Gordana D.
Venue
Communications Biology
Published
2022-03-17
Volume
5
Issue
1
Pages
236-236
ISSN
2399-3642 (ISSN-L)
OpenAlex
W4221027885
Cited by
48
References
133
Citations by year
2026: 5 · 2025: 16 · 2024: 11 · 2023: 9 · 2022: 7
FWCI
2.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R44MH10848)
  • U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R44DA044050, K08DA037465, T32DA015036, R01DA039044)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
brain-derived neurotrophic factor, intranasal drug delivery, HIV-associated neurocognitive disorders, HIV-1 Tat protein, hippocampus, neurogenesis, synaptogenesis, TrkB signaling, cognitive enhancement, blood-brain barrier, bionanoparticles
MeSH terms
Animals, Clathrin, Cognition, Drugs, Chinese Herbal, Hippocampus, HIV Infections, Brain-Derived Neurotrophic Factor, Mice, Nanoparticles, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model. https://app.cochat.ai/papers/10.1038/s42003-022-03177-3
The paper
Vitaliano, G. D., Kim, J. K., Kaufman, M. J., Adam, C. W., Zeballos, G., Shanmugavadivu, A., Subburaju, S., McLaughlin, J. P., Lukas, S. E., & Vitaliano, F. (2022). Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model. Communications Biology. https://doi.org/10.1038/s42003-022-03177-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.